The biologic effects of interleukin-7 (IL-7) and the expression of specific IL-7 membrane receptors on isolated neoplastic cells from previously untreated patients with chronic lymphocytic leukemia as well as acute leukemias were investigated in vitro. Leukemic cells were incubated for up to 6 days with various concentrations of IL-7 (0.01 to 2,000 U/mL). Neoplastic cells of the T-or B-phenotype from chronic as well as from acute leukemias proliferated in a dose-dependent manner. Cells from acute myeloid leukemias also proliferated in response to IL-7. An optimal proliferative effect was achieved between 96 and 120 hours with 200 U/mL IL-7. Combinations NTERLEUKIN-7 (IL-7), a product of stromal cells of I various organs, was initially characterized as a hematopoietic growth factor for early B cells.Ls2 It causes proliferation of pre-B and pro-B cells, but not of mature B cell^,^^^ with no evidence of differentiation of either the pro-B-or pre-B-cell compartment. Thus, IL-7 appears to provide a proliferative signal to cells of the B-lineage. Interestingly, IL-7 has now been shown to stimulate T-cell progenitors,'.' and to act as a growth factor for thymocytes, mature human T cells, and T-cell clones.829 In addition, IL-7 is mitogenic for a proportion of mature T cells in the absence of any co-mitogen. Recently, it has been described that cells from acute leukemias possess specific receptors for IL-7 and that these cells proliferate in response to IL-7.'' It has previously been shown that IL-2, IL-4, and tumor necrosis factor-a (TNF-a) provide a stimulatory signal to neoplastic B cells."-" In this report, we investigated the ability of leukemic cells of various differentiation stages to proliferate in response to IL-7 and the cellular distribution of the corresponding receptors. Our data indicate that purified neoplastic cells of various differentiation stages possess receptors for IL-7 and that IL-7 can provide a strong stimulatory signal to these cells.
I various organs, was initially characterized as a hematopoietic growth factor for early B cells.Ls2 It causes proliferation of pre-B and pro-B cells, but not of mature B cell^,^^^ with no evidence of differentiation of either the pro-B-or pre-B-cell compartment. Thus, IL-7 appears to provide a proliferative signal to cells of the B-lineage. Interestingly, IL-7 has now been shown to stimulate T-cell progenitors,'.' and to act as a growth factor for thymocytes, mature human T cells, and T-cell clones.829 In addition, IL-7 is mitogenic for a proportion of mature T cells in the absence of any co-mitogen. Recently, it has been described that cells from acute leukemias possess specific receptors for IL-7 and that these cells proliferate in response to IL-7.' ' It has previously been shown that IL-2, IL-4, and tumor necrosis factor-a (TNF-a) provide a stimulatory signal to neoplastic B cells."-" In this report, we investigated the ability of leukemic cells of various differentiation stages to proliferate in response to IL-7 and the cellular distribution of the corresponding receptors. Our data indicate that purified neoplastic cells of various differentiation stages possess receptors for IL-7 and that IL-7 can provide a strong stimulatory signal to these cells.
MATERIALS AND METHODS
Peripheral blood was obtained by venipuncture from previously untreated leukemic patients. Diagnosis was based on standard clinical, morphologic, and immunologic features. Most patients with chronic lymphocytic leukemia (CLL) were in a highly leukemic phase of the disease (Table 1) . Different untreated acute leukemias and one Burkitt lymphoma were also investigated. Immunophenotypic characteristics of these are listed in Table 2 . Informed consent was obtained in accordance with the institutional policy.
Blood was anticoagulated with heparin. In some experiments, we used cells stored previously in liquid nitrogen. Mononuclear cells (MNC) were isolated by FicollHypaque (Pharmacia, Freiburg, Germany) density-gradient centrifugation. Plastic adherent cells in MNC from all patients with B-CLL were removed by incubation of the cell suspension on petri dishes (Nunc, Wiesbaden, Germany) for 90 minutes at 37°C. The resulting cell population was depleted of T cells by rosetting for 60 minutes at 4°C with neuraminidase-treated sheep red blood cells (RBC) (CD14) and OKT3 (CD3). All leukemic B-CLL cell populations used in our experiments had less than 1% CD14+ and CD3+ cells. B-CLL cells, which proliferated after macrophage and T-cell depletion in response to IL-7, were further purified by cell sorting (fluorescence-activated cell sorter [FACS] and EPICS; Coulter, Hialeah, FL), on the basis of dual expression of CD5 and CD19. For dual-color sorts, B-CLL cells were labeled with fluorescein isothiocyanate (F1TC)-conjugated B4 (CD19) monoclonal antibody (MoAb) and phycoerythrin (PE)-conjugated Leu-1 (CD5). Before sorting, the cells were washed twice in phosphate-buffered saline (PBS) containing 2% fetal calf serum (FCS). Labeling procedures were performed at 4°C for 30 minutes. The purity of the cell populations, sorted according to forward-angle light scatter and fluorescence intensity, exceeded more than 99% determined by reanalysis.
Cells from acute leukemias were macrophage and T-cell depleted (except T-cell acute lymphoblastic leukemias [T-ALLs]) and, in some cases, further purified by FACS on the basis of expression of specific antigens.
Indirect immunofluorescence. Cells were stained in suspension with specific MoAbs by indirect immunofluorescence. Briefly, cells were incubated for 30 minutes with specific reagents, washed, and stained with FITC-conjugated goat antimouse IgG or IgM (Medac, Hamburg, Germany) for 30 minutes.
Reagents were obtained from the following sources: OKT3 (CD3), OKT4 (CD4), OKT8 (CD8), and OKTlO (CD38) from Ortho Diagnostic System (Neckargemuend, Germany); Leu-1 (CD5) and Leu-14 (CD22) from Becton Dickinson (Roedermark, Germany); B1 (CD20), B2 (CD21), B532 (CD23), M02 (CD14), plasma cell antigen-1 (PCA-I) (CD27), IL-2R (CD25), antibodies against surface Ig anti-tc, anti-A, anti-a, anti-k, and anti-6 from Coulter (Krefeld, Germany); B4 (CD19) and ION3 (CDw65) from Dianova (Hamburg, Germany). The immunophenotype of acute leukemias was characterized using the routine leukemia phenotyping program as performed by the Department of Hematology, University of Ulm, Germany. Culture conditions and proliferation assay. The rate of DNA synthesis was measured by [3H]TdR uptake. Triplicates of 4 X 10s CLL cells and 2 x 10s cells from acute leukemias were seeded in flat-bottom microtiters wells (Nunc) in a total volume of 200 pL RPMI 1640 (GIBCO, Karlsruhe, Germany) supplemented with 10% heat-inactivated FCS containing different concentrations of IL-7 (0.01 to 2,000 U/mL). Cultures were incubated for up to 144 hours at 3 7 T , 5% CO, and 98% humidity, and were pulsed with 1 pCi [3H]TdR (6.7 Ci/mmol; Amersham, Braunschweig, Germany) 7 hours before harvesting (Cell Harvester; Scatron, Lier, Norway). jncorporated radioactivity was measured by liquid scintillation counting (Packard Tricarb 1500, Frankfurt, Germany). Induction of proliferation was defined as a greater than twofold increase in counts per minute as compared with the unstimulated control.
The FCS and the medium used were tested to determine whether they contained endotoxin. Both were found to be negative. This test was performed by an IL-1 production assay with six human monocyte preparations (sensitivity < 10 pg lipopolysaccharide [LPS] S. typhi 0901/mL)." In addition, we used the polyclonal T-cell activator phytohemagglutinin (PHA, 5 pg/mL; Wellcome Diagnostica, Burgwedel, Germany) to detect possible contaminant T cells.
Highly purified IL-7 was obtained from Immunex Corporation (Seattle, WA). The specific activity of this IG7 was 2,800 Uikg protein. An MoAb against IL-7 with a neutralizing capacity of 100 NU/pg also was provided by Immunex Corporation. Further interleukins were obtained from the following sources: recombinant IL-1p (rIL-lp) (Genzyme, Boston, MA), rIL-2 (Dr H. Wagner, Department of Immunology, University of Ulm), rIL-3 (Behring, Marburg, Germany), rIL-4 (Genzyme), rIL-5 (Amersham), rIL-6 (Dr H. Wagner), rTNF-a and rTNF-p (BASF/Knoll, Ludwigshafen, Germany). Neutralizing MoAb against IL-2, IL-4, and IL-6 was obtained from Genzyme.
[1251]-rIL-2 (33.7 pCi/pg) was obtained from NEN (Dreieich, Germany). lmmunophenotypes were classified with a standard panel of antibodies. To obtain proliferation data, cells (1 x 1O6/mL) from patients with acute leukemias were incubated with IL-7 (200 U/mL) for 96 hours. Proliferation rate was determined by pulse with ['HITdR (1 pCi/well) during the last 7 hours of incubation. Data are the mean cpm 2 SD from triplicate wells. Null-ALL was defined by absence of CD1, CD2, CD5, CD10, and cytoplasmic or surface Ig expression.
Abbreviations: NT, not tested; Neg, negative; Pos, positive; FAB, French-American-British classification. For measurement of protein synthesis rates, neoplastic B cells (2 x lo6 cells/mL) were seeded in flat-bottom microtiter wells in a total volume of 200 +L. Cultures were incubated for up to 96 hours and were pulsed with 1 +Ci ['HI-leucine (54 Ciimmol, Amersham) 2 hours before cell harvesting. The further procedure has been described in detail by Okamoto et a1.I6
Radioiodination of IL-7 was performed by the lactoperoxidase method." IL-7 (5 pg) was iodinated with 1 mCi [lZsI] sodium iodide (Amersham) to a specifie radioactivity of 33.7 pCi/pg. Free iodine was removed by Sephadex G-50 superfine column (Pharmacia). Radiolabeled stocks were stored in Dulbecco's PBS and supplemented with 0.1% bovine serum albumin (BSA) at -70°C. Bioactivity was determined on B-CLL cells from patient 4, which possess receptors for IL-7 and responded well to IL-7. The maximum binding capacity and specific radioactivity were calculated from control experiments as described by Calvo et al. '' Binding assays were performed in a total volume of 0.1 mL in duplicate, with 3 to 5 X lo6 cells/sample. Washed cells were incubated for 1 hour at 3 P C or for 2 hours at Binding assays.
RESULTS
IL-7induced proliferation of neoplastic cells from CLL patients. The isolated cell samples obtained from the CLL patients contained less than 1% CD14+ and CD3' cells (except the T-CLL case 13). Incubation in culture medium alone showed a low level of ['HITdR incorporation after 24 hours with no increase, or only a slight increase up to twofold after 96 hours, as compared with 24 hours. Incubation with IL-7 initiated a proliferative effect on CLL cells. B cells from six cases as well as one T-CLL (case 13) showed a more than twofold increase of [3H]TdR incorporation (Table 3) after 96 hours of incubation as compared with the culture with medium alone. The proliferating B-cell populations were further purified by cell sorting on the basis of dual expression of CD5 and CD19. The DNA synthesis of these sorted neoplastic B-cell populations was in the range of the macrophage and T-cell-depleted populations. Increased DNA synthesis was detected after 24 hours and reached a maximum level between 96 and 120 hours (data not presented). CLL cells responded with proliferation to IL-7 over a wide dose range (0.1 to 2,000 U/mL), reaching a plateau response at the 200 U/mL dose (Fig 1) . In three of the IL-7 responsive cases (8,11, and 13) there was a corresponding increase in RNA and protein synthesis detectable (Fig 2) . Morphologic and immunophenotypic analysis indicated that only B cells had expanded during cell culture. Incubation with IL-7 did not appear to induce differentiation as measured by the expression of PCA-1 in cultured cells. The level of IG2R expression (Tac-antigen) measured by flow cytometry was found to increase during 96 hours of culture with 200 U/mL IL-7 in cases that proliferated in response to IL-7 (Fig 3) . Scatchard analysis using iodinated IL-2, indicating the expression of high affinity, forms with a kd of 200 pmol/L after incubation with IL-7 (data not presented). The IL-2R number did not increase in the cells cultured with medium alone.
The IL-7-stimulated cultures that showed a marked increase in [3H]TdR incorporation did not increase significantly in the viable cell count at 96 hours compared with the original cell count, but we could detect single mitosis. In unstimulated cultures, the viable cell count decreased to o J : half of the original count after 96 hours of incubation as determined by trypan blue dye exclusion. The IL-7-induced proliferation was completely reversed by an MoAb against IL-7 ( Table 4 IL-74nduced proliferation of cells from patients with acute ~eukemia~. We also examined peripheral blood cells from patients with de novo acute leukemia. Leukemic cells were recovered by Ficoll-Hypaque separation and further purified by plastic adherence and T-cell depletion (except the two cases of T-ALL). Furthermore, cells of case 16 were sorted by FACS on the basis of dual expression of CD19 and CDw65, cases 19 and 20 on the basis of dual expression of CDlO and CD19, and case 24 on the basis of CD20 expression ( Table 2 ). The cells were incubated with different concentrations of IL-7 (20 U/mL, 200 U/mL) for 96 hours. Leukemic cells of the immature as well as the more mature B-phenotype proliferated in response to IL-7 (Table 2). T-ALL and biphenotypic cases of acute leukemias 6-CLL cells (2 x 106/mL) were incubated for 4 days with different cytokines, IL-la to IL-6, TNF-a, and TNF-fi at concentrations of 50 UlmL. 
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that co-express lymphoid and myeloid cell surface antigens responded in a dose-dependent fashion to IL-7 with [3H]TdR incorporation. Cells from two of five patients with acute myeloid leukemia (AML) (cases 25 and 26) showed a fivefold increase in DNA synthesis after stimulation with IL-7 compared with the unstimulated culture ( Table 2) .
To establish the optimum conditions for [ (Tables 3 and 6 ). The two cases of AML that proliferated in response to IL-7 expressed receptors for IL-7 (Tables 2 and 6 the myelomonocytic AML possessed the highest numbers of low-affinity IL-7 receptors (Table 6 ).
DISCUSSION
Neoplastic B cells from CLL proliferate in response to different lymphokines, such as IL-2, IL-4, and TNF-a."." In contrast to B cells from healthy donors, the addition of co-stimulatory factors is not required. In this report, we demonstrate that IL-7 can also induce the proliferation of neoplastic T and B cells in a dose-dependent manner that does not require the addition of co-stimulatory factors. The ability of IL-7 to stimulate relatively mature neoplastic cells, as defined by surface markers (Table l) , suggests a broader role for IL-7 than those what has been previously described.2
Optimal proliferation with IL-7 was achieved with 200 U/mL and could be completely suppressed with a specific antibody to IL-7, indicating that the proliferation cannot be explained by a contaminant in the IL-7 preparation. Detection of mitoses exclusively in the IL-;'-stimulated cultures demonstrates that IL-7-induced DNA synthesis actually leads to cell division. The viable cells in unstimulated cultures decreased as compared with the original cell count during further incubation, which indicates that IL-7 stimulates at least a subpopulation, which actually proliferated. Corresponding increases in RNA and protein synthesis in cells stimulated by IL-7 suggest that an increase in ['HITdR incorporation may not have been caused by changes in thymidine pool size." Very low doses of IL-7, such as 1 U/mL, induced a marked [3H]TdR incorporation in the majority of neoplastic cells. This finding is in accordance with the results of Okazaki et al," who described a similar dose dependence on thymocytes.
IL-7-induced expression of high affinity (kd =200 pmol/L) IL-2R on neoplastic T and B cells suggests that IL-2 may play a role in the IL-7-induced proliferation. However, proliferation in the presence of IL-7 was not effected by the addition of an IL-2 antibody at any concentration of IL-7 tested, suggesting that IG7-induced proliferation was not dependent on the presence of IL-2. Our data also suggest that the observed effect of IL-7 on CLL cells is For personal use only. on September 24, 2017. by guest www.bloodjournal.org From not mediated indirectly through the action of IL-4, IL-6, or TNF-a in as much as neutralizing antibodies against these lymphokines alone or in combination had no effect on IL-7-induced proliferation. Whether IL-7 acts directly or by induction of an as yet unidentified growth factor remains to be determined.
B-CLL cells proliferating in response to IL-7 as well as nonproliferating B-CLL cells display either K or A light chains with no preference (Table 1) . B cells from patients with CLL were shown to express several antigens that have not been detected on small resting B cells yet appear after activation. These antigens include the B-cell-activation antigens IL-2R (CD2.5) and T10 (CD38).2'3" These antigens were heterogeneously expressed in our CLL cases, which suggests that the ability to proliferate in response to IL-7 is not associated with the expression of these antigens. Freedman et a]'' also report that expression of activation antigens does not correlate with proliferation.
The proliferation of AML cells in response to IL-7 suggests that the IL-7-induced stimulatory signal may not be restricted to the lymphoid lineage.
Our experiments on IL-7 receptor expression showed binding sites on all proliferative cases, including one myelomonocytic AML that possessed the highest numbers of IL-7 receptors. Park et a1 described relatively high levels of IL-7 receptor expression on bone marrow-derived macrophages, as well as on a macrophage tumor cell line,*' also indicating that IL-7 receptor expression is not restricted to the lymphoid lineage. In our studies, the concentration of IL-7 producing maximum ['HITdR incorporation (200 U/mL [2,857 pmol/L]) was in the range of receptor saturation. Scatchard analysis indicated high-and low-affinity binding sites. Binding sites have also been shown for other leukemic cell linesU and on neoplastic T and B cells from patients with acute leukemia.'" In our cases, the high-and lowaffinity receptor display correlates with IL-7-induced proliferation.
In conclusion, IL-7 can induce a growth-promoting effect on neoplastic cells. The proliferative effect acts on relatively mature neoplastic B cells and is not restricted to the lymphoid compartment. The proliferation of B-CLL cells appears to be primarily a direct effect of IL-7 not involving IL-2, although IL-7 augments the expression of IL-2R on these cells. The ability to bind radiolabeled IL-7 correlated with IL-7-induced proliferation, suggesting a direct ligandreceptor interaction is responsible for the proliferative response.
